The current stock price of CRGX is 4.47 USD. In the past month the price decreased by -1.11%. In the past year, price decreased by -75.1%.
ChartMill assigns a technical rating of 1 / 10 to CRGX. When comparing the yearly performance of all stocks, CRGX is a bad performer in the overall market: 93.99% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to CRGX. No worries on liquidiy or solvency for CRGX as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months CRGX reported a non-GAAP Earnings per Share(EPS) of -3.66. The EPS increased by 92.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -85.76% | ||
| ROE | -93.3% | ||
| Debt/Equity | 0 |
11 analysts have analysed CRGX and the average price target is 5.61 USD. This implies a price increase of 25.5% is expected in the next year compared to the current price of 4.47.
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.32 | 393.136B | ||
| AMGN | AMGEN INC | 16.18 | 196.357B | ||
| GILD | GILEAD SCIENCES INC | 16.51 | 182.665B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.73 | 117.594B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.25 | 79.341B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.21 | 42.669B | ||
| INSM | INSMED INC | N/A | 31.681B | ||
| NTRA | NATERA INC | N/A | 29.21B | ||
| BIIB | BIOGEN INC | 12.42 | 27.736B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.376B |
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. The company is headquartered in San Carlos, California and currently employs 167 full-time employees. The firm's programs, platforms, and manufacturing strategy were designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. A CAR is an engineered protein that is delivered into T cells, enabling recognition and destruction of cancer cells.
CARGO THERAPEUTICS INC
835 Industrial Road, Suite 400
San Carlos CALIFORNIA US
Employees: 167
Phone: 16504998950
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. The company is headquartered in San Carlos, California and currently employs 167 full-time employees. The firm's programs, platforms, and manufacturing strategy were designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. A CAR is an engineered protein that is delivered into T cells, enabling recognition and destruction of cancer cells.
The current stock price of CRGX is 4.47 USD. The price decreased by -1.54% in the last trading session.
CRGX does not pay a dividend.
CRGX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
CARGO THERAPEUTICS INC (CRGX) operates in the Health Care sector and the Biotechnology industry.
CARGO THERAPEUTICS INC (CRGX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.66).
CARGO THERAPEUTICS INC (CRGX) will report earnings on 2025-11-10.